IRLAB Receives Notice of Allowance for U.S. Patent

September 11, 2018

IRLAB has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding a new patent directed to novel compounds for the treatment of CNS disorders. This means the patent application is to be granted. The invention is based on discoveries using IRLAB’s discovery platform, ISP, and relates to the key compounds in the P001 program.

IRLAB has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding a new patent directed to novel compounds for the treatment of CNS disorders. This means the patent application is to be granted. The invention is based on discoveries using IRLAB’s discovery platform, ISP, and relates to the key compounds in the P001 program.

“This is an important step in our P001 discovery program and for the pursuit of the next generation of compounds effectively treating patients suffering from motor, psychiatric and cognitive disorders. We are confident that this patent will strengthen our intellectual property portfolio, enable the selection of new drug candidates, and boost our continuing effort developing improved treatments of CNS disorders”, says Dr Clas Sonesson, IRLAB’s Chief Scientific Officer.

Documents & Links